A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

CNS Malignancies
Medulloblastoma Recurrent
ATRT Recurrent
Pineoblastoma
Embryonal Neoplasm
Ependymoma Recurrent
High Grade Gliomas

Interventions

DRUG: SGT-53
RADIATION: hypofractionated radiotherapy with immunotherapy
DRUG: Nivolumab

Sponsor

Children's National Research Institute